August Bioservices Closes $23.6 Million Series A Extension to Expand U.S. Biopharma Manufacturing Capabilities
Summary
August Bioservices partners with biopharmaceutical and biotech companies to provide a wide array of services that help to accelerate the advancement of novel therapeutics along the drug development pathway. The need to expand domestic manufacturing capacity has been underscored by the pandemic and international trade disputes,” said Darren Carroll of Polaris Partners, who joined the August Bioservices board as an observer. The first expansion project, which will focus on renovating August’s existing facility, includes the addition of development and manufacturing capabilities for liquid and lyophilized vials, prefilled syringes, IV bags and terminal sterilization. “Polaris shares our focus on offering the highest quality research, development and manufacturing services to our customers as they work to provide lifesaving medications to patients who need them. For the biotech and pharma companies it serves, August is a US-based outsourcing partner with state-of-the-art instrumentation, industry-leading technical expertise, and decades of finished dose pharmaceutical manufacturing experience.